Abstract: This is a study of amniotic epithelial cells, which form the innermost layer of the amniotic membrane. These cells can be easily isolated and display peculiar and unique properties, such as plasticity and differentiation potential toward the 3 germinal layers, that may aid regeneration and/or repair of damaged or diseased tissues and organs. A robust literature based on in vitro, experimental, and clinical studies in large animals demonstrates that these cells can enhance the regeneration of tendons, bone, and articular cartilage. On the basis of these considerations, allotransplantation of human amniotic epithelial cells could be proposed for clinical trials in human orthopedic conditions.
A mniotic epithelial cells (AECs) are 1 of the 2 types of cells isolated from the amniotic membrane (AM) of mammals. In man, the AM is formed by epiblast-derived epithelial cells (AECs) and hypoblast-derived mesenchymal cells (AMSCs). 1 In particular, AECs give rise to the innermost layer of AM, in direct contact with amniotic fluid and fetus. Given the derivation from the epiblast before gastrulation, AECs might retain stem cell-like properties. 1 These cells have been accurately characterized, and a robust literature shows that they have a high level of plasticity associated with the capacity to differentiate cells of the 3 germinal layers 2-6 when exposed to exogenous growth factors or chemicals. 6 Interestingly, in addition to the customary mesenchymal lineages differentiation, we were able to demonstrate in vitro tenogenic differentiation of ovine AECs (oAECs) cocultured with equine tenocytes. 7 Another relevant feature of AECs is that they can be considered immune-privileged cells. 8 Indeed, AECs show remarkable characteristics of low immunogenicity 5, 8 and high immunomodulatory activity both in humans [9] [10] [11] [12] [13] and in animals. 14 This feature is obviously crucial for maintaining fetomaternal tolerance, and is a unique feature of the organ, placenta. This tissue is routinely discarded after birth, which largely obviates ethical concerns. Taken together, these features justify the suggestion that AECs could be proposed as good candidates to be used in cellular therapy and regenerative medicine. In this review, we present an update on the described salient characteristics of AECs and on their possible therapeutic role, focusing our attention on musculoskeletal disorders.
ISOLATION AND CHARACTERIZATION
Human amniotic epithelial cells (hAECs) can be obtained from the AM after mechanically stripping it from the underlying chorion. The protocol for isolating the cells was described by Miki and Strom in 2006. 6 Briefly, after being washed, the AM is trypsinized to release AECs from the basal layer and the mesenchymal cell layer. AECs are described 15 as medium-sized, circular-shaped cells that show a central or eccentric nucleus, 1 or 2 nucleoli, and abundant cytoplasm, usually vacuolated. In culture, the cells proliferate toward confluence in a single layer with typical cobblestone epithelial appearance. Continuing with culture and with the autocrine production of transforming growth factor β, wingless-INT, and fibroblast growth factors, 16, 17 AECs undergo the epithelial to mesenchymal transition, acquiring a fibroblast-like spindly shaped morphology.
Surface Antigens and Molecular Markers
hAECs express typical cell surface markers associated with embryonic stem cells, such as stage-specific embryonic antigens 3 and 4 and tumor-rejection antigens 1-60 and 1-81. 6, 18 Molecular markers of pluripotent cells, Oct-4 and nanog, considered necessary for self-renewal and pluripotency 19 are also expressed. 6 AECs have been studied in different species, including sheep, [20] [21] [22] horse, 23 cat, 24 and rat. 25 Despite the late embryonic origin of domestic animal amnion, 26 AECs in these animals retain early stem cell markers similar to humans, 18, 27, 28 bringing evidence to the suggestion that the maintenance of some embryonic properties does not depend only on the embryological origin of cells. Some other antigens have been described on the surface of hAECs. In vitro cultured cells express cytokeratin (a typical epithelial marker). Interestingly, the mesenchymal marker, vimentin, is also expressed during culture, 29 possibly as a sign of the epithelial-mesenchymal transition potential of AEC, as indicated by Sakuragawa et al, 30 or as a result of dedifferentiation. 29 Even though a comprehensive analysis of hAEC phenotype has been published, 3 the expression profile of hAECs varies greatly between authors, and it is quite difficult to compare them; in addition, it must be remembered that the AM contains epithelial cells with different surface markers, suggesting some differences in phenotype. 31 However, the lack of expression of the hematopoietic stem cell marker CD34 is very important, because it indicates that a cell population is not contaminated by hematopoietic stem cells. 8 
Differentiation Potential
The ability of hAECs to differentiate in vitro toward all 3 germ layers by using exogenous growth factors was first demonstrated by Miki et al in 2005. 18 Since then, this assumption has been accepted by the scientific community. For the purposes of this review, it is important to underline that hAEC can differentiate also into typical mesenchymal lineages. 13, 32, 33 To our knowledge, the differentiation of hAEC toward a tenogenic lineage has been demonstrated only very recently by in vivo transplantation of hAEC into experimentally induced Achilles tendon defects in sheep. 34 This aspect is particularly relevant as, unlike other mesenchymal tissues, adult tendons do not regenerate spontaneously, but heal through the production of fibrotic scar, with poor tissue quality and mechanical properties. 35 Differentiation toward multiple lineage was demonstrated also in AEC isolated from the placenta of different animal species, including horse, 23 cat, 24 and sheep. 7, 14, 20, 21, 34, 36, 37 In particular, as regards orthopedic regenerative medicine, differentiation toward osteogenic and chondrogenic lineages has been demonstrated for equine AEC, 23 oAEC, 20, 21 and feline AEC. 24 As for hAEC, tenogenic differentiation of oAEC has been reported by our group both in vitro 7 and in vivo. 20, 22 Immunology Immunologic behavior is of paramount importance since the fascinating hypothesis suggested by Miki and Strom in 2006 6 with regard to the possibility to complete banks with all major histocompatibility complexes could be realized. Until then, only allo and xenotransplantation protocols could be undertaken for preclinical and clinical studies. Moreover, the suppression of the immune response, which is activated following an injury, has been very recently proposed as a contributing factor of AEC to the regeneration of damaged tissue. 32 AECs display low immunogenicity and secrete immunoregulatory molecules both in humans 8, 13 and in investigated animal species. 27 Freshly isolated AECs express very low levels of MCH-1 and lack MCH-2 in cat, 25 sheep, 16 and horse 23 as well as low levels of HLA-1 and lack of HLA-2 in man. 3, 8, 38 Even if Baban et al 39 refuted this hypothesis, it has been suggested that the inhibition of T-cell proliferation, which takes place to protect the fetus from maternal T cells, 3 is triggered by the expression of the tryptophan catabolisin enzyme IDO (indoleamine 2,3-dioxygenase). 31, 40, 41 The immunomodulatory effect of AEC on T and B lymphocytes is well documented 42 and occurs in a dose-dependent manner. 13 AM-derived cells were able to inhibit monocyte differentiation in the absence of cell-cell contact, suggesting the involvement of soluble factors. 42, 43 Magatti et al 42 also demonstrated that both mesenchymal, and epithelial AM populations contribute to dendritic maturation, exploiting soluble factors. In addition to these observations, in a recent study, Mauro et al 44 demonstrated the recruitment of M1 and M2 macrophages, and stated that this represents a key event during the early phase of tendon regeneration in experimental allotransplantation. The aforementioned peculiar and unique features render AECs ideal candidates to develop cell therapy protocols, encouraging the development of allotransplantation or xenotransplantation settings on different domestic animal models.
Tumorigenicity
Unlike other cell types used for therapeutic purposes (mainly induced pluripotent stem cells, which have high tumorigenicity), allo and xenotransplantation of AECs into immune competent organisms are well tolerated, without incurring in any rejection or tumorigenic derives. 18 ,28,32
POSSIBLE THERAPEUTIC ROLE
Cell-induced regeneration may take place through many processes, but 2 major mechanisms are recognized: the in situ transdifferentiation toward the lineage of host-damaged tissues and/or the improvement of paracrine factors that modulate the proliferation/differentiation of resident progenitor cells. 34 Moreover, very recently, a third mechanism has been proposed, which provides that the bioactive molecules secreted by stem cells could exert a modulation of the immune response which, in turn, could help tissue regeneration by suppressing the immune response activated by the injury. 43 However, in vitro studies demonstrated that the phenotype and the biological properties of AM-derived cells can be strongly affected by some factors related to the cell origin and/or by cell manipulation. 14, 16, [45] [46] [47] It is therefore logical to assume that, when exposed to an extremely complex microenvironment, such as a live tissue, the cell behavior could dramatically change in an unpredictable way. For this reason, in vivo preclinical studies and clinical trials in animals, and particularly in companion (dog, cat, and horse) and farm animals (sheep, goat, bovine, and pig), have a mandatory role in the translational process before proposing AECs for therapeutic use in man. Furthermore, it should be remembered that many diseases affecting humans also pose a problem in veterinary patients with similar pathology and etiopathogenesis. 34 This is particularly true for orthopedic diseases in dogs and horses, which perform an athletic (eg, sport horses and agility dogs) or a working career (service dogs). Even though the AM has a long history in humans, therapy biology and properties of cells isolated from placental tissues started to result in a consistent number of publications only about 1 decade ago. 26 In addition, ethical and legal considerations prevent clinical experimentation in man: to our knowledge, the only published scientific article concerning an experimental procedure dates back to 1981. 48 Therefore, in vivo transplantation of AEC is related only to experimental, preclinical, and clinical studies in animals.
Tendon Disorders
Experimental, preclinical, and clinical studies on tendon disorders in horses have a very high translational value, considering that equine and human tendinopathies have many similarities in their pathophysiology, as equine superficial digital flexor tendon recapitulates the main biomechanical and histologic characteristics of human Achilles tendons. [49] [50] [51] Ovine species also play an important role in musculoskeletal experimental and preclinical trials, because of their high translational value, given their similarities with humans in terms of weight, mechanical exertion, and reproductive gestational outcomes. [52] [53] [54] [55] AM-derived cells, namely AMSCs, were first used by Lange-Consiglio et al 56 in horses. In addition to good tolerance after allogeneic transplantation, the same group, in a very interesting comparative study, demonstrated a greater effectiveness of AMSCs compared with bone marrow mesenchymal stem cells in the treatment of spontaneous tendon and ligament injuries. As regards AEC, our research group has deepened the knowledge on the role of these cells by carrying out preclinical studies adopting an allotransplantation approach on a validated ovine experimentally injured calcaneal tendon model (Fig. 1) . 20, 44, 57 These studies demonstrated the capability of oAECs to improve and accelerate tendon regeneration, and also to improve the biomechanical properties of newly formed tissue. 20 Transplanted AECs stimulate tendon regeneration partly through a paracrine stimulation of the host's damaged tissues. 20, 44, 57 In addition, results of studies with allo and xenotransplantation of oAEC clearly demonstrated that transplanted cells undergo differentiation toward tenocyte and can synthetize collagen type I (Fig. 2) , thus contributing to tissue regeneration through a direct release of the major tendon extracellular matrix proteins. 20, 22 From a clinical point of view, the results that we obtained with xenotransplantation of oAEC in spontaneous 22 and experimental superficial digital flexor tendon lesions in horses 51 unequivocally showed a very good clinical outcome, as confirmed by statistical analysis of ultrasonographic parameters, together with the absence of any adverse reaction to oAECs xenotransplantation. Moreover, histologic examination demonstrated an almost complete restoration of normal tendon architecture with an optimal alignment of tendon fibers. 51 For the first time, we could demonstrate a very positive result also in a chronic case. 51 
Bone Disorders
Placenta-derived cells enhance osteogenesis in an experimentally induced defect of the radius in dogs. 58 Amniotic fluid stem cells have also demonstrated a definite osteogenic potential when implanted into experimental critical size femoral defects in a rat model. 59 The presence of blood vessels in the inner sections of the scaffolds seeded with cells suggests that these cells could potentially be used to induce bone regeneration and angiogenesis in nonunion bone defects. 59 The allotransplantation of oAEC in experimental tibial defects in sheep showed that these cells can exert an osteogenic effect when implanted into the bone defect. 21 Labeled AECs survived within the defect, supporting a robust production of newly formed bone. Similarly, the enhanced osteogenesis stimulated by AECs has been exploited in experimental sinus lift procedures in sheep. 60, 61 Articular Cartilage Disorders hAMSCs have the potential to differentiate, in vivo, into chondrocytes, suggesting a therapeutic potential to manage cartilage defects. 62 Considering that AECs also show the same chondrocitic lineage differentiation, it would be logical to hypothesize the same therapeutic potential also for AECs. However, to date, only 1 report demonstrated the synthesis of newly formed cartilage tissue in a full-thickness femoral cartilage defect in a sheep model treated with fresh or cryopreserved AM. 63 Further studies are necessary to investigate this very important aspect.
CONCLUSIONS
There is consensus agreement that AECs, and other AM-derived stem cells, could contribute to the management of many orthopedic conditions, and a robust literature started to clarify the mechanism supporting the regenerative thrust. Finally, the results obtained with experimental, preclinical, and clinical studies on animals, support the premise for the beginning of clinical trials of allotransplantation in human patients. 
